Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.
Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.


Regulatory News:



Novo Nordisk A/S and BIOCORP Production SA (Paris:ALCOR) announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which

Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023:
Agilent Intelligent Mass Spectrometry Solutions to Inspire at ASMS 2023


Agilent Technologies Inc. (NYSE: A) today announced new mass spectrometry solutions on show at the 71st ASMS Conference on Mass Spectrometry and Allied Topics, being held June 4 - 8 in Houston

Owkin Powers a New Era in Oncology Research with MOSAIC – An Unprecedented $50 Million Spatial Atlas of Cancer Cells
Owkin Powers a New Era in Oncology Research with MOSAIC – An Unprecedented $50 Million Spatial Atlas of Cancer Cells


Owkin, Nanostring (NASDAQ:NSTG), and world-leading cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum

Chemed Corporation to Present at the Jefferies 2023 Healthcare Conference
Chemed Corporation to Present at the Jefferies 2023 Healthcare Conference


Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2023 Healthcare Conference on Thursday, June 8, 2023, at approximately 11:30 a.m. (ET) at the New

Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System
Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System


Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease

Dexcom Announces Upcoming Conference Presentation
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO  THE NUMBER OF SHARES AND VOTING RIGHTS  MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Acadia Healthcare to Participate in Jefferies Global Healthcare Conference
Acadia Healthcare to Participate in Jefferies Global Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Jefferies Global Healthcare Conference, June 7-9, 2023, in New York City.



In connection

EQS-News: M1 Kliniken AG publishes Q1 figures 2023:  Strong growth and disproportionate increase in operating result
EQS-News: M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result
EQS-News: M1 Kliniken AG publishes Q1 figures 2023: Strong growth and disproportionate increase in operating result
NanoString to Webcast Presentation from Jefferies Healthcare Conference
NanoString to Webcast Presentation from Jefferies Healthcare Conference


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

EQS-News: Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
EQS-News: Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
EQS-News: Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
EQS-News: Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results
Agilent Reports Second-Quarter Fiscal Year 2023 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.72 billion for the second quarter ended April 30, 2023, an increase of 6.8% compared to the second quarter of 2022 and up 9.5% on a

QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

MD Medical Group Investments Plc: MD Medical Group announces intention to delist GDRs from the LSE
MD Medical Group Investments Plc: MD Medical Group announces intention to delist GDRs from the LSE
MD Medical Group Investments Plc: MD Medical Group announces intention to delist GDRs from the LSE
Agilent to Present at Jefferies and Goldman Sachs Healthcare Conferences
Agilent to Present at Jefferies and Goldman Sachs Healthcare Conferences


Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
NanoString to Host Conference Call on Monday, May 22, 2023, to Provide Comments on Decision of the Regional Court of Munich
NanoString to Host Conference Call on Monday, May 22, 2023, to Provide Comments on Decision of the Regional Court of Munich


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will host a conference call on

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents
Agilent to Appeal Patent Office Decision on CRISPR gRNA Patents


Agilent Technologies Inc. (NYSE: A), announced today the company intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
NanoString nimmt Stellung zur Entscheidung des Landgerichts München
NanoString nimmt Stellung zur Entscheidung des Landgerichts München


NanoString Technologies, Inc. (Nasdaq: NSTG), ein führender Anbieter von biowissenschaftlichen Werkzeugen für die Forschung und die translationale Forschung, reagierte heute auf die jüngste

Agilent Announces Cash Dividend of 22.5 Cents Per Share
Agilent Announces Cash Dividend of 22.5 Cents Per Share


Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 22.5 cents per share of common stock will be paid on July 26, 2023, to all shareholders of record as of the close of

NanoString Responds to Decision of the Regional Court of Munich
NanoString Responds to Decision of the Regional Court of Munich


NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today responded to the Regional Court of Munich’s recent decision